Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200 at the European Congress of Rheumatology (EULAR) 2026 in London, UK. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The Phase 1 data from healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity with no impact on serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
The company is currently dosing patients with moderate to severe rheumatoid arthritis (RA) in the Phase 1 study, with data expected by year-end 2026. These initial results suggest that LFD-200 may offer a targeted approach to deliver glucocorticoids to disease-relevant immune cells while avoiding systemic side effects commonly associated with steroid therapies. Glucocorticoids are effective in treating inflammatory conditions but are limited by long-term toxicities such as adrenal suppression, osteoporosis, and metabolic disturbances.
Lifordi’s ADC platform leverages the success of ADCs in oncology to address inflammatory diseases. LFD-200 is designed to bind to specific immune cells and release the glucocorticoid payload intracellularly, potentially achieving high local concentrations while minimizing systemic exposure. The data presented at EULAR 2026 included pharmacokinetic and pharmacodynamic profiles showing dose-dependent anti-inflammatory markers without cortisol suppression, indicating a favorable safety margin.
According to the company, the Phase 1 trial is a first-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of LFD-200 in healthy participants and subsequently in patients with RA. The ongoing patient portion will provide further insights into efficacy and safety in the target population. Lifordi has also applied its drug delivery approach to other payloads, including antisense oligonucleotides, siRNA, and small molecules.
Lifordi is backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures. The company is committed to transforming the treatment of immune and inflammatory diseases by applying ADC technology to deliver potent anti-inflammatory agents directly to disease-causing cells. For more information, visit www.lifordi.com or follow them on LinkedIn.
